

# Seto Wk

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9578925/seto-wk-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

209  
papers

6,546  
citations

42  
h-index

73  
g-index

261  
ext. papers

8,138  
ext. citations

5.9  
avg, IF

6.09  
L-index

#	Paper	IF	Citations
209	Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.. <i>The Lancet Global Health</i> , <b>2022</b> , 10, e278-e287	13.6	6
208	Phenotypic Changes of PD-1 and GITR in T Cells Are Associated With Hepatitis B Surface Antigen Seroclearance. <i>Journal of Clinical Gastroenterology</i> , <b>2022</b> , 56, e31-e37	3	0
207	RNA interference as a novel treatment strategy for chronic hepatitis B infection.. <i>Clinical and Molecular Hepatology</i> , <b>2022</b> ,	6.9	6
206	Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction.. <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 813783	5.7	0
205	Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma.. <i>Hepatology International</i> , <b>2022</b> , 1	8.8	0
204	Role of Serum M2BPGi Levels in Predicting Persistence of Advanced Fibrosis in Chronic Hepatitis B Virus Infection.. <i>Digestive Diseases and Sciences</i> , <b>2022</b> , 1	4	
203	The optimal screening strategy for chronic hepatitis B virus infection in China - AuthorsReply.. <i>The Lancet Global Health</i> , <b>2022</b> , 10, e793	13.6	
202	HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy. <i>Hepatology</i> , <b>2021</b> , 73, 2167-2179	11.2	17
201	Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). <i>Gastroenterology</i> , <b>2021</b> ,	13.3	9
200	Response to Liu et al., and Björnsson and Björnsson. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1091-1092	0.7	1
199	First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 123	3	3
198	Tumor suppressive role of mitochondrial sirtuin 4 in induction of G2/M cell cycle arrest and apoptosis in hepatitis B virus-related hepatocellular carcinoma. <i>Cell Death Discovery</i> , <b>2021</b> , 7, 88	6.9	5
197	Gut microbiome and resistome changes during the first wave of the COVID-19 pandemic in comparison with pre-pandemic travel-related changes. <i>Journal of Travel Medicine</i> , <b>2021</b> , 28,	12.9	2
196	Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251552	3.7	1
195	Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. <i>Hepatology International</i> , <b>2021</b> , 15, 881-891	8.8	0
194	Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. <i>Viruses</i> , <b>2021</b> , 13,	6.2	5
193	Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. <i>Hepatology International</i> , <b>2021</b> , 15, 901-911	8.8	1

192	Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. <i>Diabetes Care</i> , <b>2021</b> , 44, 2089-2097	14.6	6
191	Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 1315-1326	4	5
190	Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. <i>Gut</i> , <b>2021</b> , 70, 775-783	19.2	18
189	Trends in Liver Transplantation for Chronic Hepatitis B in an Era of Highly Potent Antiviral Therapies. <i>Liver Transplantation</i> , <b>2021</b> , 27, 134-139	4.5	1
188	Chronic liver disease: Global perspectives and future challenges to delivering quality health care. <i>PLoS ONE</i> , <b>2021</b> , 16, e0243607	3.7	5
187	Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , <b>2021</b> , 36, 134-145	3.5	1
186	Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. <i>Journal of Gastroenterology</i> , <b>2021</b> , 56, 479-488	6.9	6
185	Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma.. <i>Liver Cancer</i> , <b>2021</b> , 10, 606-614	9.1	2
184	Detection of the hepatitis B surface antigen in patients with occult hepatitis B using an assay with enhanced sensitivity.. <i>Journal of Clinical Microbiology</i> , <b>2021</b> , jcm0220421	9.7	0
183	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	17
182	Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed. <i>JHEP Reports</i> , <b>2020</b> , 2, 100112	10.3	9
181	Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 800-806	13.4	19
180	Modelling NAFLD disease burden in four Asian regions-2019-2030. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 801-811	6.1	31
179	Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 899-908	6.1	9
178	Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B. <i>Current Hepatology Reports</i> , <b>2020</b> , 19, 293-301	1	3
177	Crowdsourcing to promote hepatitis C testing and linkage-to-care in China: a randomized controlled trial protocol. <i>BMC Public Health</i> , <b>2020</b> , 20, 1048	4.1	2
176	ACE (Angiotensin-Converting Enzyme) Inhibitors/Angiotensin Receptor Blockers Are Associated With Lower Colorectal Cancer Risk: A Territory-Wide Study With Propensity Score Analysis. <i>Hypertension</i> , <b>2020</b> , 76, 968-975	8.5	14
175	HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. <i>Scientific Reports</i> , <b>2020</b> , 10, 802	4.9	9

174	Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. <i>Gut and Liver</i> , <b>2020</b> , 14, 665-668	4.8	2
173	1509-P: Development of a Noninvasive Fibrosis Score for Chinese Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. <i>Diabetes</i> , <b>2020</b> , 69, 1509-P	0.9	
172	Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down-regulating the nuclear factor-kappa B signaling. <i>Journal of Digestive Diseases</i> , <b>2020</b> , 21, 38-45	3.3	11
171	Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B. <i>Hepatology</i> , <b>2020</b> , 72, 818-828	11.2	5
170	A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 397-406	3.4	8
169	Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. <i>Hepatology International</i> , <b>2020</b> , 14, 35-46	8.8	14
168	Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1573-1574	13.4	17
167	Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00236	4.2	9
166	High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line <i>Helicobacter pylori</i> therapy in southern China: a municipality-wide, multicentre, prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 3391-3394	5.1	4
165	Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2020</b> , 40, 2719-2731	7.9	11
164	Association Between Nonvitamin K Antagonist Oral Anticoagulants or Warfarin and Liver Injury: A Cohort Study. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1513-1524	0.7	6
163	Statins Were Associated with a Reduced Gastric Cancer Risk in Patients with Eradicated Infection: A Territory-Wide Propensity Score Matched Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 493-499	4	15
162	Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 449-456	6.9	28
161	Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 320-325	4	11
160	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, 1924-1933	7	17
159	Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. <i>Hepatology International</i> , <b>2019</b> , 13, 148-156	8.8	8
158	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 220, 940-950	7	2
157	Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 818-827	3.4	19

156	Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. <i>Liver International</i> , <b>2019</b> , 39, 1217-1225	7.9	5
155	Epidemiology, characteristics, and survival of post-colonoscopy colorectal cancer in Asia: A population-based study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1545-1553	4	12
154	Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients. <i>Gut</i> , <b>2019</b> , 68, 1979-1985	19.2	22
153	Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment. <i>Annals of Hematology</i> , <b>2019</b> , 98, 215-218	3	15
152	Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2019</b> , 19, 789	4.8	7
151	Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1473-1480	3.4	7
150	Diabetes Increases Risk of Gastric Cancer After Eradication: A Territory-Wide Study With Propensity Score Analysis. <i>Diabetes Care</i> , <b>2019</b> , 42, 1769-1775	14.6	21
149	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3630-3641	4	
148	Long-term data on entecavir treatment for treatment-naive or lamivudine-resistant chronic hepatitis B infection in kidney transplant recipients. <i>Transplant Infectious Disease</i> , <b>2019</b> , 21, e13143	2.7	3
147	Application of Big Data analysis in gastrointestinal research. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 2990-3008	5.6	20
146	Future Therapies for Functional Cure of Chronic HBV: Review of Investigational Drugs in Phase 1 and 2 Development. <i>Current Hepatology Reports</i> , <b>2019</b> , 18, 503-511	1	5
145	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 1398-1408	5.6	9
144	Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 4715-4726	5.6	7
143	New Biomarkers of Chronic Hepatitis B. <i>Gut and Liver</i> , <b>2019</b> , 13, 589-595	4.8	23
142	Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 1817-1823	4	9
141	Novel developments of hepatitis B: treatment goals, agents and monitoring tools. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 109-120	3.8	20
140	Hepatitis B Virus: Asian Perspective <b>2019</b> , 99-116		2
139	Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1410-1412	6.9	7

138	Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 484-489	9.7	34
137	Fatal pancytopenia due to albendazole treatment for strongyloidiasis. <i>IDCases</i> , <b>2018</b> , 12, 112-116	2	1
136	96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 672-681	13.4	180
135	Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 730-737	6.1	42
134	Aspirin and Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 743-749	9.7	32
133	Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 101-106	5.5	2
132	An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 483-491	5.5	4
131	Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. <i>Hepatology</i> , <b>2018</b> , 68, 462-472	11.2	39
130	Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 121-128	13.4	9
129	Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 575-583.e2	6.9	46
128	Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 43-54	6.1	105
127	Prognostic Value of Hepatorenal Function By Modified Model For End-stage Liver Disease (MELD) Score in Patients Undergoing Tricuspid Annuloplasty. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	24
126	Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S87	13.4	7
125	Relationship between hepatitis B core-related antigen and chronic hepatitis B outcome in HBeAg negative patients: a 10-year longitudinal study. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S478	13.4	3
124	Impact of wild-type and carboxyl-terminal truncated hepatitis B virus X on hepatocyte proliferation. <i>World Chinese Journal of Digestology</i> , <b>2018</b> , 26, 760-768	0.1	
123	Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 97-104	3.4	42
122	Rates of metachronous adenoma after curative resection for left-sided or right-sided colon cancer. <i>Intestinal Research</i> , <b>2018</b> , 16, 619-627	4.1	1
121	Risk Factors for Graft Steatosis after Liver Transplantation using Controlled Attenuation Parameter Measurements. <i>Transplantation</i> , <b>2018</b> , 102, S863	1.8	

120	Chronic hepatitis B virus infection. <i>Lancet, The</i> , <b>2018</b> , 392, 2313-2324	40	206
119	Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> ,	6.9	24
118	Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. <i>Scientific Reports</i> , <b>2018</b> , 8, 7958	4.9	23
117	Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. <i>Clinical and Translational Gastroenterology</i> , <b>2018</b> , 9, 163	4.2	18
116	Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 501-509	6.1	22
115	The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection. <i>Liver International</i> , <b>2017</b> , 37, 1287-1294	7.9	4
114	Letter: is body-mass index really associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B? AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 483	6.1	
113	Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 654-661	3.4	44
112	Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. <i>Antiviral Research</i> , <b>2017</b> , 144, 1-7	10.8	28
111	Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 1064-1074	6.9	9
110	Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. <i>Hepatology</i> , <b>2017</b> , 66, 1036-1044	11.2	70
109	Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. <i>Hepatology</i> , <b>2017</b> , 65, 1451-1461	11.2	60
108	Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. <i>Liver International</i> , <b>2017</b> , 37, 995-1001	7.9	91
107	Hepatitis B core protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , <b>2017</b> , 21, 1153-1159	4.2	23
106	Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. <i>Clinical and Translational Gastroenterology</i> , <b>2017</b> , 8, e116	4.2	35
105	Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. <i>Transplantation</i> , <b>2017</b> , 101, 2391-2398	1.8	3
104	Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. <i>Clinical and Translational Gastroenterology</i> , <b>2017</b> , 8, e125	4.2	64
103	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. <i>Clinical and Translational Gastroenterology</i> , <b>2017</b> , 8, e100	4.2	20

102	Response to Toyoda et al. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 970	0.7	
101	Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 202-206	3.3	11
100	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 1230-1233	4	14
99	Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 275-281	13.4	97
98	Nonalcoholic fatty liver disease in Asia: emerging perspectives. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 164-174	6.9	59
97	<i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. <i>Oncotarget</i> , <b>2017</b> , 8, 47507-47517	2.3	23
96	Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 7716-7726	5.6	21
95	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 7863-7874	5.6	7
94	Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. <i>Journal of Gastroenterology</i> , <b>2016</b> , 51, 487-95	6.9	20
93	Viral hepatitis: Immune tolerance in HBV infection: danger lurks. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2016</b> , 13, 627-628	24.2	4
92	Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1788-1795	0.7	51
91	A Territory-Wide Study on the Seroprevalence of Hepatitis B Virus in the General Population after Universal Hepatitis B Immunization ERA in Hong Kong, China. <i>Journal of Hepatology</i> , <b>2016</b> , 64, S378	13.4	3
90	New pharmacological approaches to a functional cure of hepatitis B. <i>Clinical Liver Disease</i> , <b>2016</b> , 8, 83-88	2.2	15
89	Relation of Tricuspid Regurgitation to Liver Stiffness Measured by Transient Elastography in Patients With Left-Sided Cardiac Valve Disease. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 640-646	3	11
88	Hepatitis B: treatment choice and monitoring for response and resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 697-707	4.2	10
87	DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 383-92	4.1	18
86	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. <i>Gut</i> , <b>2016</b> , 65, 887-8	19.2	25
85	Prevention and management of hepatitis B virus reactivation in cancer patients. <i>Hepatology International</i> , <b>2016</b> , 10, 407-14	8.8	16



84	Emerging drugs for the treatment of hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , <b>2016</b> , 21, 183-93	3.7	8
83	Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection. <i>Clinical Microbiology and Infection</i> , <b>2016</b> , 22, 290.e1-3	9.5	6
82	Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. <i>Gut and Liver</i> , <b>2016</b> , 10, 332-9	4.8	307
81	Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , <b>2016</b> , 11, e0148493	3.7	17
80	Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. <i>Liver International</i> , <b>2016</b> , 36, 642-50	7.9	5
79	Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. <i>Journal of Clinical Gastroenterology</i> , <b>2016</b> , 50, 286-94	3	36
78	Hepatitis B virus full-length genomic mutations and quasispecies in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1638-45	4	8
77	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 185-195	18.8	237
76	Interleukin-1 $\beta$ increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. <i>Oncology Letters</i> , <b>2016</b> , 11, 2919-2924	2.6	15
75	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2016</b> , 1, 196-206	18.8	259
74	Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 1071-1079	6.1	19
73	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , <b>2015</b> , 64, 667-72	19.2	148
72	O009 : A prospective study of hepatitis B reactivation in patients with prior HBV exposure undergoing hematopoietic stem cell transplantation: Reactivation association with graft-versus-host disease. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S194	13.4	2
71	Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study. <i>Liver International</i> , <b>2015</b> , 35, 854-9	7.9	5
70	Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. <i>Oncotarget</i> , <b>2015</b> , 6, 34941-52	3.3	38
69	Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0139478	3.7	8
68	High prevalence of non-alcoholic fatty liver disease in the Chinese - results from the Hong Kong liver health census. <i>Liver International</i> , <b>2015</b> , 35, 542-9	7.9	59
67	Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 825-30	3.4	20

66	Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1764-70	0.7	15
65	Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , <b>2014</b> , 20, 1173-80	9.5	77
64	Hepatitis Viruses and Hepatocellular Carcinoma <b>2014</b> , 181-192		2
63	Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus. <i>Journal of Clinical Microbiology</i> , <b>2014</b> , 52, 3209-15	9.7	9
62	Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1028-34	4	41
61	Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 701-7	7	9
60	New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. <i>PLoS ONE</i> , <b>2014</b> , 9, e86449	3.7	28
59	Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. <i>PLoS ONE</i> , <b>2014</b> , 9, e99028	3.7	11
58	Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3736-43	2.2	223
57	Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 428-34	4	67
56	Entecavir treatment in kidney transplant recipients infected with hepatitis B. <i>Clinical Transplantation</i> , <b>2014</b> , 28, 1010-5	3.8	19
55	HLA-DP and Interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 533-9	4	4
54	Artificial neural network accurately predicts hepatitis B surface antigen seroclearance. <i>PLoS ONE</i> , <b>2014</b> , 9, e99422	3.7	7
53	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , <b>2013</b> , 7, 327-34	8.8	2
52	Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. <i>Journal of Viral Hepatitis</i> , <b>2013</b> , 20, 470-7	3.4	22
51	Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. <i>Hepatology</i> , <b>2013</b> , 58, 923-31	11.2	70
50	Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. <i>Clinical Gastroenterology and Hepatology</i> , <b>2013</b> , 11, 1004-10.e1	6.9	98
49	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 709-16	13.4	43

48	Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 942-8	0.7	94
47	Reply to Liao et al. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 622	11.6	1
46	Use of liver stiffness measurement for liver resection surgery: correlation with indocyanine green clearance testing and post-operative outcome. <i>PLoS ONE</i> , <b>2013</b> , 8, e72306	3.7	26
45	HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 1695-703	11.6	52
44	Defining normal liver stiffness range in a normal healthy Chinese population without liver disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e85067	3.7	29
43	Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. <i>PLoS ONE</i> , <b>2013</b> , 8, e66920	3.7	31
42	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 8887-94	5.6	33
41	Acute-on-chronic liver failure in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 662-9	4	51
40	Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. <i>Hepatology International</i> , <b>2012</b> , 7, 98-105	8.8	24
39	Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. <i>Hepatology International</i> , <b>2012</b> , 7, 119-26	8.8	9
38	A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. <i>PLoS ONE</i> , <b>2012</b> , 7, e32622	3.7	53
37	High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. <i>PLoS ONE</i> , <b>2012</b> , 7, e43087	3.7	59
36	A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. <i>Hepatology</i> , <b>2012</b> , 56, 812-9	11.2	68
35	Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1255-62	1.6	15
34	Future prevention and treatment of chronic hepatitis B infection. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 725-34	3	4
33	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 195-200	13.4	24
32	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 522-528	13.4	30
31	Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. <i>Lancet Oncology</i> , <b>2011</b> , 12, 568-74	21.7	427

30	Ketamine-induced cholangiopathy: a case report. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1004-5	7	22
29	748 OUTCOME OF 4-YEAR TREATMENT OF ENTECAVIR FOR TREATMENT-NAIVE CHRONIC HEPATITIS B. <i>Journal of Hepatology</i> , <b>2011</b> , 54, S301	13.4	14
28	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, 738-44	3.4	38
27	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, e200-5	3.4	44
26	The use of transient elastography in the management of chronic hepatitis B. <i>Hepatology International</i> , <b>2011</b> , 5, 868-875	8.8	13
25	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , <b>2011</b> , 10, 235-243		21
24	Stability of hepatitis B surface antigen over time: implications for studies using stored sera. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 1900-4	19.7	7
23	Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years. <i>Hepatology</i> , <b>2011</b> , 53, 1148-53	11.2	11
22	Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. <i>Hepatology</i> , <b>2011</b> , 54, 829-36	11.2	106
21	Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1264-7	11.7	117
20	Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1766-73	0.7	51
19	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 2715-25	5.1	139
18	Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 646-54	7	76
17	The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1007-8	0.7	14
16	Nucleic acid testing for the detection of HBV DNA. <i>Hepatitis Monthly</i> , <b>2011</b> , 11, 847-8; author reply 849	1.8	1
15	A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. <i>PLoS ONE</i> , <b>2011</b> , 6, e23077	3.7	61
14	Nucleic Acid Testing for the Detection of HBV DNA. <i>Hepatitis Monthly</i> , <b>2011</b> , 11, 847-848	1.8	1
13	Epidemiology and clinical features of Shewanella infection over an eight-year period. <i>Scandinavian Journal of Infectious Diseases</i> , <b>2010</b> , 42, 757-62		22

12	Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. <i>Gut</i> , <b>2010</b> , 59, 1389-93	19.2	47
11	Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 1116-22	0.7	44
10	Natural history of chronic hepatitis C: genotype 1 versus genotype 6. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 444-8	13.4	33
9	Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. <i>Hepatology International</i> , <b>2010</b> , 4, 716-22	8.8	26
8	Profile of pre-S deletions in the natural history of chronic hepatitis B infection. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1843-9	19.7	12
7	Clarithromycin-amoxicillin-containing triple therapy: a valid empirical first-line treatment for <i>Helicobacter pylori</i> eradication in Hong Kong?. <i>Helicobacter</i> , <b>2009</b> , 14, 505-11	4.9	38
6	Mutational analysis for Wilson's disease. <i>Lancet, The</i> , <b>2009</b> , 374, 662	4.0	9
5	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , <b>2009</b> , 14, 679-685	1.6	8
4	The effect of intragastric balloon placement on weight loss and type 2 diabetes control. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 162-4; author reply 164-5	6.1	8
3	Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 1295-303	1.6	75
2	Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease. <i>Antiviral Therapy</i> , <b>2007</b> , 12, 1295-1304	1.6	175
1	Statins associate with lower risk of biliary tract cancers: A systematic review and meta-analysis. <i>Cancer Medicine</i> ,	4.8	1